BIOA B Stock Overview
BioArctic AB (publ) develops biological drugs for patients with neurodegenerative disorders in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BIOA B from our risk checks.
BioArctic AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr203.80 |
| 52 Week High | kr392.00 |
| 52 Week Low | kr191.50 |
| Beta | -0.17 |
| 1 Month Change | -6.86% |
| 3 Month Change | -13.50% |
| 1 Year Change | -14.01% |
| 3 Year Change | 120.09% |
| 5 Year Change | 159.45% |
| Change since IPO | 602.76% |
Recent News & Updates
Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)
Apr 13
News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 19Recent updates
Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)
Apr 13News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 19News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 03Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues
Dec 23With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case
Nov 12BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be
Jul 21Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results
Jul 15New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)
Jul 07Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade
May 06Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth
Mar 13Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher
Nov 30We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn
Sep 16We're Interested To See How BioArctic (STO:BIOA B) Uses Its Cash Hoard To Grow
Apr 04We Think BioArctic (STO:BIOA B) Can Easily Afford To Drive Business Growth
Dec 05BioArctic AB (publ) (STO:BIOA B) Shares Could Be 42% Below Their Intrinsic Value Estimate
Sep 15BioArctic (STO:BIOA B) Is In A Strong Position To Grow Its Business
Aug 23Is BioArctic AB (publ) (STO:BIOA B) Trading At A 41% Discount?
Jun 03Shareholders Will Probably Not Have Any Issues With BioArctic AB (publ)'s (STO:BIOA B) CEO Compensation
Apr 29Is BioArctic's (STO:BIOA B) Share Price Gain Of 291% Well Earned?
Mar 14Shareholder Returns
| BIOA B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -0.7% | -1.8% | -0.7% |
| 1Y | -14.0% | -6.3% | 8.8% |
Return vs Industry: BIOA B underperformed the Swedish Biotechs industry which returned -6.1% over the past year.
Return vs Market: BIOA B underperformed the Swedish Market which returned 8.9% over the past year.
Price Volatility
| BIOA B volatility | |
|---|---|
| BIOA B Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: BIOA B's share price has been volatile over the past 3 months.
Volatility Over Time: BIOA B's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 88 | Gunilla Osswald | www.bioarctic.se |
BioArctic AB (publ) develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. It also develops ABBV-0805, for treating Parkinson’s disease.
BioArctic AB (publ) Fundamentals Summary
| BIOA B fundamental statistics | |
|---|---|
| Market cap | kr18.00b |
| Earnings (TTM) | kr229.25m |
| Revenue (TTM) | kr620.08m |
78.5x
P/E Ratio29.0x
P/S RatioIs BIOA B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOA B income statement (TTM) | |
|---|---|
| Revenue | kr620.08m |
| Cost of Revenue | kr89.63m |
| Gross Profit | kr530.45m |
| Other Expenses | kr301.20m |
| Earnings | kr229.25m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 17, 2024
| Earnings per share (EPS) | 2.60 |
| Gross Margin | 85.55% |
| Net Profit Margin | 36.97% |
| Debt/Equity Ratio | 0% |
How did BIOA B perform over the long term?
See historical performance and comparison